DESTINY-Breast03 Phase 3 Study Results
•
DESTINY-Breast04 Establishes T-DXd as the New Standard
of Care in HER2-low, HR+/HR- MBC
Daiichi-Sankyo
DESTINY-Breast04
•
T-DXd is the first HER2-targeted therapy to
demonstrate unprecedented statistically significant
and clinically meaningful improvement in PFS and
OS versus TPC
• Similar magnitude of benefit across all subgroups,
including HER2 IHC status and prior CDK4/6i use
•
Safety is consistent with the known safety profile
and showed an overall positive benefit-risk
T-DXd €
TPC
DESTINY-Breast04 establishes HER2-low (IHC 1+,
IHC 2+/ISH-) mBC as a new targetable patient
population, with T-DXd as a new standard of care
T-DXd
TPC
Median
Efficacy in All Patients
(HR+ and HR-)
Progression-Free Survival
5.1 mo
9.9 mo
Hazard ratio: 0.50, P < 0.0001
Overall Survival
23.4 mo
16.8 mo
Hazard ratio: 0.64, P = 0.001
CDK4/61, cyclin-dependent kinase 4/6 inhibitors; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; IHC, immunohistochemistry; ISH, in situ hybridization; mBC, metastatic breast cancer; OS, overall survival; PFS, progression-free
survival; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice.
ASCO 2022 #LBA3 Plenary Session
21View entire presentation